Thermo Fisher Scientific Inc


Want a discount? Become a member by purchasing Annual Subscription!
SKU: TMO-1 Category:


Thermo Fisher continues to be an excellent ‘Buy’ with the Covid-19 recovery in progress. While the pandemic made it difficult for healthcare facilities to increase the purchase of Thermo Fisher Scientific equipment, the company’s Covid-19 diagnostics helped its revenues climb by a staggering 26% in 2020. With the pandemic impact receding gradually, the testing revenues are expected to slow by the end of 2021 but these will be compensated by the growth in the core life science business. The company has had an interesting set of developments off late with the recent alliance with the University of California, San Francisco to open a cell therapy cGMP manufacturing and of course the $17.4 billion purchase of PPD. Thermo Fisher is on track for a solid year ahead and we maintain our ‘Buy’ rating with a revised target price.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $496 annual subscription!